Navigation Links
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Date:11/22/2011

SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the closing of its previously announced public offering of 21,800,000 shares of its common stock, including 2,800,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering price of $3.75 per share.  The net proceeds from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $77.4 million.

Deutsche Bank Securities Inc. acted as sole book-running manager, Leerink Swann LLC acted as co-lead manager and Cowen and Company, LLC acted as co-manager for the offering.  The securities described above were offered by Cadence pursuant to a shelf registration statement that had been previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311-3901, or by telephone at: (800) 503-4611, or by email at: prospectus.cpdg@db.com.  This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cadence Pharmaceuticals, Inc.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and Drug ... VISIQ, in the U.S. VISIQ is the ... greater mobility, performance and simplicity into a single miniaturized ... for more OB patients. This breakthrough ultrasound ...
(Date:7/24/2014)... July 24, 2014  To help health care ... that could impact patient care and the bottom ... Watch , "Innovations in Cardiovascular Devices."  ... guidance and details on promising new technologies that ... understand how these options impact the supply chain.   ...
(Date:7/24/2014)... 24, 2014 Second Quarter and ... and Chief Executive Officer effective September 2, 2014 ... million , BioGlue ® revenues grew 14 ... revenues grew 22 percent year-over-year to $1.1 million ... percent year-over-year to $1.7 million , Tissue processing ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17
... CITY, Calif., April 28, 2011 OncoMed Pharmaceuticals, Inc., ... cells or tumor-initiating cells, today announced that the FDA ... OncoMed to commence Phase 1 clinical testing.   ... receptors in the Wnt signaling pathway and is the ...
... Reportlinker.com announces that a new market research ... http://www.reportlinker.com/p0487248/Advanced-Lung-Cancer-in-Patient-Smoker-with-Squamous-Cell-Clinical-Insights-from-a-US-Oncologists-Survey.html Advanced Lung ... Insights from a US Oncologists, Survey ... cancer in a situation involving a smoker with ...
Cached Medicine Technology:OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5 2OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5 3Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey 2Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey 3
(Date:7/24/2014)... Just as fitness and health professionals ... own financial and marketing strength to be important as ... the next level by using the most powerful communication ... Broadcast, Call Tracking and SMS texting solutions . ... messages are quickly become integral in marketing and communication ...
(Date:7/24/2014)... Kathleen Doheny HealthDay ... Parents of obese children often don,t view their kids as ... inactivity, according to a new study. The children of ... obesity clinic at the Hasbro Children,s Hospital in Providence, R.I. ... very good," said study researcher Dr. Kyung Rhee, now an ...
(Date:7/24/2014)... July 24, 2014 This year the ... Light Electric and Jackson National Life, will be held on ... 7 am, the Kids Fun Run at 7:50 am, the ... at 9 a.m. , “The Walk to End Alzheimer’s unites ... dedication in the fight against this devastating disease, “stated Linda ...
(Date:7/24/2014)... A new study led by the Translational Genomics ... bacteria, viruses and the immune system during HIV infection. ... potential to infect others based on their blood ... virus in their semen despite having low levels in ... of the virus can be found in different parts ...
(Date:7/24/2014)... As the age of marriage and ... as a way to ensure future family building options ... advancing reproductive age. Vitrification technology, a fast freeze method ... technology that allows a woman to have multiple eggs ... which are then stored for future use. When circumstances ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4
... research leads to groundbreaking conclusions. Valuable research data all ... unexposed to the light of day, and unused by ... dark data, is now being set free with the ... Research Notes, a new open access journal, is publishing ...
... NEW YORK, Feb. 26 On February 25, ... DGMS.PK) (http://www.digimedical.com ),updated the investment community in ... in the interview include an overview of the,company ... opportunity,and upcoming milestones for which investors should watch., ...
... of UPMC has been selected to join an effort ... to collect and study information necessary to understand the ... called primary sclerosing cholangitis (PSC). , The Studies of ... effort initiated, funded and organized by The Musette and ...
... R.I. Adults and teens that underwent surgery as infants ... face to appear uneven still have a degree of facial ... Hasbro Childrens Hospital surgeon. , The study, published in the ... coronal synostosis, a type of craniosynostosis, in which the bones ...
... "It is not clear that the,benefits of ... or other effects such as dental fluorosis," according ... Fluoride chemicals are added to 2/3 of U.S. ... is found in dental products,supplements and virtually all ...
... Court, WILMINGTON, Del., Feb. 26 The following,statement ... W.Va., zinc smelter,class action lawsuit late Monday. The statement ... Mobley., "We are extremely disappointed by the rulings ... the recent rulings and the earlier,jury verdicts. We believe ...
Cached Medicine News:Health News:Shining light on science's 'dark data:' New venture ensures a fuller scientific record 2Health News:WallSt.net (www.wallst.net) Updates Investment Community Through All-New Interview With digiMedical Solutions 2Health News:Children's Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids 2Health News:Facial asymmetry persists despite surgery to correct congenital deformity 2Health News:Fluoride May Damage the Brain, New Report Says 2Health News:DuPont Responds to Spelter, W.Va. Lawsuit Rulings 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: